THE DEFINITIVE GUIDE TO P-3FAX-NEU5AC

Hepatic impairment No dose adjustment is required in sufferers with delicate or average (Baby-Pugh A or B) hepatic impairment (see portion five.two). Exposure to midostaurin and its active metabolite CGP62221 is substantially lower in patients with significant hepatic impairment than that in sufferers with standard hepatic purpose (see part five.Th